Literature DB >> 19527107

Overview of stem cell therapy for Crohn's disease.

Gerald Wayne Dryden1.   

Abstract

BACKGROUND: Crohn's disease (CD) therapy is rapidly evolving. Recent and ongoing clinical trials using immunologically active stem cells (SC) for the treatment of CD demonstrate the potential for this novel therapy to induce complete and long-lasting remission of symptoms in settings where 'standard' therapies have been unsuccessful. OBJECTIVE/
METHODS: This review of SC, including mesenchymal stem cell (MSC) therapy for CD discusses how the immunological effects of MSC may correct some of the pathophysiological defects underpinning CD, and examines the latest clinical trial data providing evidence of their efficacy in the treatment of Crohn's disease. RESULTS/
CONCLUSIONS: Given the beneficial effects on mucosal healing seen in animal models of inflammation and results from early clinical trials, MSC may serve as a candidate therapy for patients who have failed to respond to biological therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527107     DOI: 10.1517/14712590902956615

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  13 in total

Review 1.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

Review 2.  The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease.

Authors:  Brent R Weil; Mariuxi C Manukyan; Jeremy L Herrmann; Aaron M Abarbanell; Jeffrey A Poynter; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

Review 3.  Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review.

Authors:  Jan Voswinkel; Sabine Francois; Jean-Marc Simon; Marc Benderitter; Norbert-Claude Gorin; Mohamad Mohty; Loïc Fouillard; Alain Chapel
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

4.  Cord-blood-derived mesenchymal stromal cells downmodulate CD4+ T-cell activation by inducing IL-10-producing Th1 cells.

Authors:  Silvia Selleri; Mame Massar Dieng; Simon Nicoletti; Isabelle Louis; Christian Beausejour; Françoise Le Deist; Elie Haddad
Journal:  Stem Cells Dev       Date:  2013-01-04       Impact factor: 3.272

Review 5.  Mesenchymal stem cells for the treatment of neurodegenerative disease.

Authors:  Nanette Joyce; Geralyn Annett; Louisa Wirthlin; Scott Olson; Gerhard Bauer; Jan A Nolta
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

6.  Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop.

Authors:  Andrea L DiCarlo; Radia Tamarat; Carmen I Rios; Marc Benderitter; Christine W Czarniecki; Theresa C Allio; Francesca Macchiarini; Bert W Maidment; Jean-Rene Jourdain
Journal:  Radiat Res       Date:  2017-06-12       Impact factor: 2.841

7.  Mesenchymal stromal cells from donors varying widely in age are of equal cellular fitness after in vitro expansion under hypoxic conditions.

Authors:  Troy C Lund; Amanda Kobs; Bruce R Blazar; Jakub Tolar
Journal:  Cytotherapy       Date:  2010-08-31       Impact factor: 5.414

Review 8.  Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.

Authors:  Jan Voswinkel; Sabine Francois; Norbert-Claude Gorin; Alain Chapel
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 9.  Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease.

Authors:  Scott D Olson; Kari Pollock; Amal Kambal; Whitney Cary; Gaela-Marie Mitchell; Jeremy Tempkin; Heather Stewart; Jeannine McGee; Gerhard Bauer; Hyun Sook Kim; Teresa Tempkin; Vicki Wheelock; Geralyn Annett; Gary Dunbar; Jan A Nolta
Journal:  Mol Neurobiol       Date:  2011-12-09       Impact factor: 5.590

10.  Immunogenicity of allogeneic mesenchymal stem cells.

Authors:  Sabine Schu; Mikhail Nosov; Lisa O'Flynn; Georgina Shaw; Oliver Treacy; Frank Barry; Mary Murphy; Timothy O'Brien; Thomas Ritter
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.